Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q16543

UPID:
CDC37_HUMAN

ALTERNATIVE NAMES:
Hsp90 chaperone protein kinase-targeting subunit; p50Cdc37

ALTERNATIVE UPACC:
Q16543; Q53YA2

BACKGROUND:
Hsp90 co-chaperone Cdc37, identified by alternative names such as Hsp90 chaperone protein kinase-targeting subunit and p50Cdc37, is integral to protein homeostasis. It binds various kinases, enhancing their interaction with the Hsp90 complex, thus stabilizing and promoting their activity. Cdc37 also plays a role in inhibiting HSP90AA1 ATPase activity, underlining its significance in protein regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Hsp90 co-chaperone Cdc37 holds promise for identifying novel therapeutic avenues. Given its essential role in kinase regulation and protein stabilization, targeting Cdc37 could lead to innovative treatments in diseases where protein misfolding or dysfunction is a factor.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.